Your SlideShare is downloading. ×
0
Gliptins
Gliptins
Gliptins
Gliptins
Gliptins
Gliptins
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Gliptins

2,720

Published on

gliptin basics on how they work

gliptin basics on how they work

1 Comment
3 Likes
Statistics
Notes
No Downloads
Views
Total Views
2,720
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
21
Comments
1
Likes
3
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Gliptins background
  • 2. New drugs for DM
    • In DM, several pharmacologic interventions have undesirable side effects, including hypoglycemia and weight gain.
    • Drugs targeting the incretin pathway are the latest addition to the available antidiabetes agents.
    • Incretin-based therapy is either delivered:
      • orally (dipeptidyl peptidase-4 [DPP-4]) inhibitors or
      • injected subcutaneously (glucagon-like peptide-1 [GLP-1] mimetics and analogues).
  • 3. India
    • Eli Lilly has Byetta (exenatide injection)– [GLP-1 agonist]
    • There are 3 DPP-4 inhibitors currently available
      • Sitagliptin [JANUVIA – MERCK]
      • saxagliptin, [ONGLYZA - BMS] and
      • Vildagliptin [VILDAGLIPTIN – NOVARTIS]
  • 4. DPP-4
    • Dipeptidyl peptidase-4 inhibitors are effective with a low incidence of hypoglycemia and no weight gain either as a single or combination therapy in lowering
      • glycated hemoglobin,
      • fasting and
      • postprandial glucose levels.
  • 5. How DPP-4 works?
    • The digestive system breaks down food into sugar (glucose).
    • This increases signals, called incretins.
    • Incretins tell the pancreas to release insulin in response to food.
    • In type 2 DM, the pancreas doesn't release enough insulin or the body's cells may not use insulin properly.
    • This leads to rise in blood sugar level.
  • 6. How DPP-4 works?
    • In response to a meal, active glucagon-like peptide-1 (GLP-1) is secreted by the L cells of the intestines.
    • Without the presence of a gliptin, GLP-1 is rapidly inactivated and degraded by the enzyme dipeptidyl peptidase IV (DPP4);
    • when a gliptin is present, it binds to DPP4, allowing GLP-1 to remain active.
    • Active GLP-1 causes the pancreas to increase insulin release and decrease glucagon release.

×